Results 81 to 90 of about 38,381 (226)

Botulinum toxin type A success rates and predictive factors for favourable outcomes in paediatric patients with acquired esotropia.

PLoS ONE
PurposeThis study aimed to assess the efficacy of botulinum toxin type A in treating childhood-acquired comitant esotropia and identify predictive factors of treatment success.MethodsThis retrospective, consecutive, non-comparative cohort study included ...
Narisa Rattanalert, Teechaya Nonboonyawat, Supaporn Tengtrisorn, Penny Singha, Orapan Aryasit, Juthamat Witthayaweerasak, Manupol Tangthongkum   +6 more
doaj   +1 more source

From Toxin to Treatment: A Narrative Review on the Use of Botulinum Toxin for Autonomic Dysfunction

Toxins
Since its regulatory approval over a half-century ago, botulinum toxin has evolved from one of the most potent neurotoxins known to becoming routinely adopted in clinical practice.
Lucas Rempel, Raza N. Malik, Claire Shackleton, Martín Calderón-Juárez, Rahul Sachdeva, Andrei V. Krassioukov   +5 more
doaj   +1 more source

Expanding the Phenotype of PARK‐PRKN to Spastic Paraplegia: A Report of Two Cases

Movement Disorders Clinical Practice, EarlyView.
Nicolas Geoffre, Thomas Ollivier, Guillaume Baille, Luc Defebvre, Vincent Huin, Eugenie Mutez   +5 more
wiley   +1 more source

Save the Bladder: Continent Urinary Diversion as Best Practice for Patients With Refractory Neurogenic Lower Urinary Tract Dysfunction

Neurourology and Urodynamics, EarlyView.
ABSTRACT Introduction Refractory neurogenic lower urinary tract dysfunction presents an obstinate clinical problem. For patients who fail nonsurgical measures, we advocate for bladder‐sparing, continent urinary diversion as the optimal approach to management.
Brian W. Chao, Sean P. Elliott
wiley   +1 more source

Phenotyping Overactive Bladder—Part 1: Are There Different Types of Urgency and Can They be Translated to Clinical, Urodynamic and Radiological Phenotyping? ICI‐RS 2025

Neurourology and Urodynamics, EarlyView.
ABSTRACT Introduction Overactive bladder (OAB) is defined as urinary urgency, usually accompanied by increased daytime frequency and/or nocturia, with urgency urinary incontinence (OAB‐wet) or without (OAB‐dry), in the absence of urinary tract infection or other detectable disease.
John E. Speich, D. Carolina Ochoa, Pradeep Tyagi, Apostolos Apostolidis, Sanjay Sinha, Claire Hentzen, Marcus Drake, Paul Abrams, Alan J. Wein, Michel Wyndaele   +9 more
wiley   +1 more source

Botulinum Toxin Type A for Pediatric Torticollis: A Review of Clinical Research

Toxins
Pediatric torticollis, predominantly resulting from congenital muscular torticollis, is characterized by unilateral shortening of the sternocleidomastoid muscle, leading to head tilt and limited cervical mobility.
Na-Yoen Kwon, Soo-Hyun Sung, Hyun-Kyung Sung   +2 more
doaj   +1 more source

“What Medical Management Should Be First Line for Bladder Storage Symptoms in NLUTD”—Pro Botox

Neurourology and Urodynamics, EarlyView.
ABSTRACT Objectives Neurogenic lower urinary tract dysfunction (NLUTD) severely impairs patient quality of life (QoL). While oral medications are often first‐line treatments, their high failure rates and side effects limit their effectiveness. Thus, we argue for the use of intravesical botulinum toxin A (BoNT‐A) injections as a first‐line alternative ...
Vada Furlan, Alyssa Kobayashi, Zhina Sadeghi   +2 more
wiley   +1 more source

Returning to Marathons: Complete Restoration of Exercise with Runner's Dystonia After Globus Pallidus Internus Deep Brain Stimulation

Movement Disorders, EarlyView.
Arthur Thevathasan, Kristian Bulluss, Katya Kotschet, Wesley Thevathasan   +3 more
wiley   +1 more source

How Can We Personalize the Delivery of Onabotulinumtoxin‐A for Patients With Neurogenic Lower Urinary Tract Dysfunction?

Neurourology and Urodynamics, EarlyView.
ABSTRACT Background & Aims Neurogenic lower urinary tract dysfunction (NLUTD) can produce bothersome urinary symptoms, impact quality of life, and in some cases, lead to deterioration of upper urinary tract function. Intradetrusor injection of onabotulinumtoxin‐A (BoNT‐A) is approved for NLUTD in patients who have an inadequate response to or ...
Shirley L. Wang, William I. Jaffe, Ariana L. Smith   +2 more
wiley   +1 more source

Endoscopic small bowel therapies for type 2 diabetes

Nutrition in Clinical Practice, EarlyView.
Abstract Type 2 diabetes is a global epidemic despite current medical treatments. Many patients are not responsive to medications, and patients with obesity are hesitant about bariatric surgery. Studies investigating the metabolic effects of Roux‐en‐Y gastric bypass have increasingly demonstrated that the duodenum plays a key role in the ...
Roma Patel, Zehra Naseem, Prisha Gattu, Stephen Firkins, Roberto Simons‐Linares   +4 more
wiley   +1 more source